树突状细胞和肿瘤细胞融合疫苗的研究进展

随着树突状细胞（DC）在体外的大量扩增和融合技术的飞速发展，肿瘤细胞与DC融合所获得的融合瘤苗已经成为国内外肿瘤免疫治疗的焦点。DC融合瘤细胞在共刺激信号存在的条件下，加工处理递呈肿瘤相关性抗原（TAA）和肿瘤特异性抗原（TSA），诱导特异性抗肿瘤细胞毒性T淋巴细胞（CTL），逆转机体对肿瘤抗原的耐受，是一种有广阔应用前景的免疫治疗方法，为肿瘤患者的治疗开辟了一条新的途径。

Study progress about dendritic tumor fusion cell-based vaccine

With the mass amplification of dendritic cells (DC) in vitro and the fast development of fusion technique, dendritic/tumor fusion cell-based vaccine has been a focus of tumor immunotherapy worldwide.In the presence of costimulatory signals, fusions of DCs and tumor cells can process and present tumor associated antigens(TAAs) and tumor specific antigens(TSAs), and subsequently induce specific antitumor cytotoxic T Lymphocytes(CTL) and lead to the inversion of tolerance induction. This strategy might be developed into a new way of tumor therapy.